Pioglitazone for the Treatment of Alcohol Use Disorder
Key facts
- Who runs it
- VA Office of Research and Development
- Where
- Long Beach and Minneapolis, United StatesSee the 2 sites
- Trial code
- Status
- Completed
- People taking part
- 201 people enrolled
- Started
- 17 Jul 2019
- Ended
- 29 Mar 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Brief Behavioral Compliance Enhancement Treatment
- Record updated
- 13 June 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- DSM-5 diagnosis of at least moderate alcohol use disorder using the SCID
- A mean of six heavy drinking days per month for the 3-months prior to baseline
- Drinking at least 14 drinks for men or 7 drinks for women, or more per week for the 4 weeks preceding the screening visit
- Willingness to provide contact information to confirm study follow-up appointments
- Ability to perform informed consent
- Female subjects: a negative pregnancy test
- Serum ALT < 3 times reference range
- Stable psychiatric medication doses the month prior to baseline visit (antidepressant, antipsychotic, subjects may have changes in trazodone for sleep)
Who cannot take part
- Taking medications known to have significant drug interactions with the study medication (CYP2C8 inhibitors or inducers, antihyperglycemic medications)
- Currently being treated for AUD with a medication (naltrexone, naltrexone injectable, acamprosate, topiramate, disulfiram and gabapentin)
- Current DSM-5 diagnosis of moderate to severe psychoactive substance use disorder (i.e. cocaine, opiates, methamphetamine) other than cannabis or nicotine
- Medical conditions contraindicating pioglitazone pharmacotherapy (e.g., congestive heart failure, clinically significant edema, clinically significant liver disease, hypoglycemia, diabetes, history of bladder cancer)
- Cognitive or physical impairment that precludes study participation
- Currently and seriously suicidal (i.e., plan and intent)
- Impending incarceration
- Pregnant or planning to become pregnant during the course of the trial or nursing for female patients
- Unwillingness to sign a written informed consent form
- Unwillingness to use a barrier method of birth control during the study for female patients
Where in United States
- VA Long Beach Healthcare System, Long Beach, CALong Beach, United States
- Minneapolis VA Health Care System, Minneapolis, MNMinneapolis, United States
About the trial
What the trial wants to find out
Alcohol Use Disorder (AUD) is common among Veterans but medication treatment is used infrequently and the impact of these treatments are small to moderate at best. Pioglitazone, a medication FDA approved for diabetes, has been shown in pre-clinical studies to reduce alcohol. The proposed study will test the efficacy of pioglitazone to reduce alcohol use in a double-blind placebo controlled trial. Investigators plan to compare pioglitazone to placebo in 200 Veterans who have an AUD and who are currently drinking alcohol at two Veterans Affairs Health Care Centers. The primary hypothesis is that Veterans with an AUD who are currently drinking alcohol will have a greater reduction in alcohol use following treatment with pioglitazone compared to those treated with placebo.
The 2 groups in the trial
- PioglitazoneTreatment being tested
Pioglitazone titrated to 45mg by mouth each day
Treatment: Brief Behavioral Compliance Enhancement Treatment
- PlaceboPlacebo, for comparison
placebo, identical 45mg pill
Treatment: Brief Behavioral Compliance Enhancement Treatment
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized Trial of Pioglitazone for the Treatment of Alcohol Use Disorder
- Record updated
- 13 June 2025